Prospective Open-Label Study Of Andexanet Alfa In Patients
Enrolling By Invitation
18 years - 85 years
All
Phase
2
10 participants needed
1 Location
Brief description of study
Andexanet, a rationally designed, recombinant analog of endogenous human FXa, has been developed to rapidly and potently reverse FXa inhibition and restore physiologic coagulation. This study will examine the use of Andexanet inIn patients requiring urgent surgery who are being treated with a direct or indirect FXa inhibitor,
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Urgent Surgery
-
Age: 18 years - 85 years
-
Gender: All
Male or Female Age ≥ 18 and < 85 years old. Requires urgent surgical intervention that must occur within 12 hours
Updated on
04 Aug 2024.
Study ID: 843561
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
